Clinical Trials Logo

Conjunctivitis, Allergic clinical trials

View clinical trials related to Conjunctivitis, Allergic.

Filter by:

NCT ID: NCT01337557 Enrolling by invitation - Clinical trials for Allergic Conjunctivitis

Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses

Start date: May 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess if BEPREVE (bepotastine besilate ophthalmic solution) 1.5% will have an effect on contact lens wear in patients with contact lens intolerance due to allergic conjunctivitis.

NCT ID: NCT01332188 Completed - Clinical trials for Allergic Conjunctivitis

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

AC-170
Start date: April 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.

NCT ID: NCT01326858 Completed - Clinical trials for Allergic Conjunctivitis

Safety and Comfort of AL-4943A Ophthalmic Solution

Start date: April 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.

NCT ID: NCT01320553 Completed - Clinical trials for Allergic Conjunctivitis

Effect of Different Concentrations of 1334H on Allergic Conjunctivitis

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.

NCT ID: NCT01294969 Completed - Clinical trials for Allergic Conjunctivitis

Patient Perception Study for AL-4943A

Start date: September 2010
Phase: Phase 4
Study type: Interventional

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.

NCT ID: NCT01289431 Completed - Clinical trials for Conjunctivitis, Allergic

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.

NCT ID: NCT01287338 Terminated - Clinical trials for Seasonal Allergic Conjunctivitis to Ragweed

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.

NCT ID: NCT01282138 Completed - Clinical trials for Allergic Conjunctivitis

Assessment of Alcon's Ocular Image Quantification System

Start date: December 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate ocular responses with different allergen provocation methods.

NCT ID: NCT01275105 Completed - Clinical trials for Allergic Conjunctivitis

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

Start date: January 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival allergen challenge (CAC) model. It is hypothesized that low-dose brimonidine tartrate ophthalmic solution will be more effective than vehicle in the prevention of conjunctival redness induced by conjunctival allergen challenge when instilled prior to the allergen challenge.

NCT ID: NCT01272089 Completed - Clinical trials for Allergic Conjunctivitis

A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

Start date: May 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study.